Novartis | NVS - Equity Capital And Reserves


Novartis reported $38.93B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bausch Health Companies USD -2.06B 1.5B Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Drreddys Laboratories INR 380.46B 376.31B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
J&J USD 81.19B 358M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 1.89B 58.06M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sanofi EUR 73.14B 1.43B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
Zoetis USD 3.23B 98M Mar/2026